

### PATENT COOPERATION T. .. ATY

## From the INTERNATIONAL BUREAU To: **PCT NOTIFICATION OF ELECTION** United States Patent and Trademark Office (PCT Rule 61.2) (Box PCT) Crystal Plaza 2 Washington, DC 20231 **ETATS-UNIS D'AMERIQUE** Date of mailing (day/month/year) \*\*\*\* 30 September 1997 (30.09.97) in its capacity as elected Office International application No. Applicant's or agent's file reference 19191.0001/P Barr. PCT/US96/20577 International filing date (day/month/year) Priority date (day/month/year) 19 December 1996 (19.12.96) 21 December 1995 (21.12.95) **Applicant** MADISON, Edwin, L. et al The designated Office is hereby notified of its election made: X in the demand filed with the International Preliminary Examining Authority on: 21 July 1997 (21.07.97) Sina notice effecting later election filed with the International Bureau on: MANAGE ...

Section of the sectio	
	*
The election X was	
was not	
made before the expiration of 19 months from the priority date or, where Rule 32 applic. Rule 32.2(b).	es, within the time limit under
•	
Register 1 and 1 a	
3 - · · ·	
No service	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

A CONTRACTOR OF THE STATE OF TH

Authorized officer

D. Ybarra

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35

# PATENT COOPERATION To ...ATY

•				
	From the INTERNATIONAL BUREAU			
PCT	То:			
NOTIFICATION OF ELECTION (PCT Rule 61.2)	United States Patent and Trademark Office (Box PCT) Crystal Plaza 2 Washington, DC 20231 ETATS-UNIS D'AMERIQUE			
Date of mailing: 23 October 1997 (23.10.97)	in its capacity as elected Office			
International application No.:	Applicant's or agent's file reference:			
PCT/US96/20577	19191.0001/P			
International filing date:	Priority date:			
19 December 1996 (19.12.96)	21 December 1995 (21.12.95)			
Applicant: MADISON, Edwin, L. et al				
The designated Office is hereby notified of its election mad  X in the demand filed with the International preliminary.	Examining Authority on:			
21 July 1997 (:	21.07.97)			
	national Bureau on:			
2. The election X was was not	late or where Pula 22 applies within the time limit works.			
made before the expiration of 19 months from the priority of Rule 32.2(b).	late or, where note 32 applies, within the time ilmit under			

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer:

J. Zahra

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35

 $\tau \tau$ 

 $\cdot \ 1 \\ \cdot \ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot \\ \cdot$ 



### PCT

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: WO 97/39021 (11) International Publication Number: A1 C07K 1/00, 14/00, 16/00, 17/00, C12P (43) International Publication Date: 23 October 1997 (23.10,97) 21/02, 21/04, 21/08, A61K 39/395, 39/40, 39/42, 38/00, G01N 33/53 PCT/US96/20577 (81) Designated States: AU, CA, JP, US, European patent (AT, BE, (21) International Application Number: CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT. SE). 19 December 1996 (19.12.96) (22) International Filing Date: **Published** (30) Priority Data: 21 December 1995 (21.12.95) US With international search report. 60/009,028 (71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US). (72) Inventors: and (75) Inventors/Applicants (for US only): MADISON, Edwin, L. [US/US]; 615 Stratford Court #3, Del Mar, CA 92014 (US). SMITH, Jeffrey, W. [US/US]; 12602-6 Carmel Country Road, San Diego, CA 92130 (US). (74) Agents: SELBY, Elizabeth et al.; Needle & Rosenberg, Suite 1200, 127 Peachtree Street, N.E., Atlanta, GA 30303 (US).

(54) Title: TARGETED THERAPEUTIC OR DIAGNOSTIC AGENTS AND METHODS OF MAKING AND USING SAME

#### (57) Abstract

The present invention provides a targeted therapeutic or diagnostic agent comprising (a) a therapeutic or diagnostic functional entity linked to one of the following: (a) an isolated peptide mimetic that specifically binds a selected target; (b) an isolated, optimized, high-affinity polyamino acid that specifically binds a selected target; (c) an isolated protein surface loop that specifically binds a selected target, wherein the protein surface loop is not endogenous to the functional entity. The invention additionally provides methods of targeting therapeutic or diagnostic agents to a target. Additionally provided is a method of targeting a therapeutic agent to a platelet using the present agents, and methods of treating diseases and disorders associated with blood clots. Specifically provided is a recombinant targeting protein wherein the surface loop is the HCDR3 of monoclonal antibody Fab-9, the second protein is human tissue type plasminogen activator (t-PA), and the target is platelet glycoprotein GPIIb/IIIa (integrin aIIb\(\theta\)I).

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of Americ
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JР	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# B

# PATENT COOPERATION TREATY

# **PCT**

1		
REC'D	11 5 APR	1998
WIPO		1000
PORT	_ P	CT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION		ication of Transmittal of International Examination Report (Form PCT/IPEA/416)	
International application No.	International filing date (day/m		Priority date (day/month/year)	
PCT/US96/20577	19 DECEMBER 1996	<i>,</i> ,	21 DECEMBER 1995	
International Patent Classification (IPC) of Please See Supplemental Sheet.	or national classification and IPC	<u> </u>		
Applicant THE SCRIPPS RESEARCH INSTITUT	E			
Examining Authority and is a  2. This REPORT consists of a t  This report is also accompleen amended and are the	transmitted to the applicant a total of sheets.  paried by ANNEXES, i.e., sheet	ts of the desc	ription, claims and/or drawings which have g rectifications made before this Authority.	
These annexes consist of a to	tal of sheets.			
3. This report contains indication	s relating to the following its	ems:		
I X Basis of the repor	t			
II Priority				
III Non-establishmen	t of report with regard to no	velty, invent	ive step or industrial applicability	
IV Lack of unity of i	nvention	-		
V X Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
VI Certain documents cited				
VII Certain defects in the international application				
VIII Certain observations on the international application				
Date of submission of the demand	Date	of completion	of this report	
21 JULY 1997	24	MARCH 19	98	
Name and mailing address of the IPEA/U Commissioner of Patents and Tradema Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	urka Pr	CL N/RAB	of solo olling to	

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US96/20577

L	Basis f	th rep rt	
1.	This report hunder Article	as been drawn on the e 14 are referred to in	basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation this report as "originally filed" and are not annexed to the report since they do not contain amendments):
	x	the internations	l application as originally filed.
	X	the description,	pages 1-42 , as originally filed.
			pages NONE , filed with the demand.
			pages NONE , filed with the letter of
			pages, filed with the letter of
	x	the claims,	Nos. 1-55 , as originally filed.
			Nos. NONE , as amended under Article 19.
			Nos. NONE , filed with the demand.
			Nos. NONE , filed with the letter of
			Nos, filed with the letter of
	x	the drawings,	sheets/fig 1-4 , as originally filed.
	لتتنا		sheets/fig NONE , filed with the demand.
			sheets/fig NONE , filed with the letter of
			sheets/fig, filed with the letter of
2.	The amen	dments have result	ed in the cancellation of:
	x	the description,	pages NONE
	×	the claims,	Nos. NONE
	x	the drawings,	sheets/fig NONE
3	Th to	is report has been e go beyond the disclo	stablished as if (some of) the amendments had not been made, since they have been considered source as filed, as indicated in the Supplemental Box Additional observations below (Rule 70.2(c)).
4	. Addition	al observations, is	necessary:

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US96/20577

Novelty (N)	Claims	1-55	YES
	Claims	NONE	NO
Inventive Step (IS)	Claims	NONE	YES
	Claims	1-55	NO
Industrial Applicability (IA)	Claims	1-55	YES
musular Application (17)	Claims	NONE	NO
Duarte et al. [AIDS Research ar Hearst et al. [Prot. Engineer. 7:	nd Human 1411-142 are inserte	nimier et al. [Biochem. 33: 2055-2062 (1997). Retroviruses 10: 235-239 (1994)], and 1 (1994)]. Backstrom et al. teach hybrid and into cholera toxin subunit carrier proteins on et al., Shin, S-U., Shin et al., Bei et al.	

### INTERNATIONAL SEARCH REPORT

International application No. PCT/US96/20577

	SSIFICATION OF SUBJECT MATTER				
US CL	IPC(6) : Please See Extra Sheet. US CL : Please See Extra Sheet.				
	o International Patent Classification (IPC) or to both	national classification and IPC	· · · · · · · · · · · · · · · · · · ·		
	.DS SEARCHED ocumentation searched (classification system follower	d by classification symbols)			
U.S. :	530/350, 387.3, 388.25, 388.7; 424/133.1, 145.1,		.7		
Dogumento	tion searched other than minimum documentation to the	e extent that such documents are included	in the fields seasohed		
Documentat	don searched outer dian imminum documentation of the	e extent that such documents are mended	in the fields scarched		
Flectronic d	lata base consulted during the international search (na	ame of data base and, where practicable	search terms used)		
	EDLINE, CAPLUS, WPIDS	and or our own and, whore practically	, search coins ascay		
C. DOC	UMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where ap	ppropriate, of the relevant passages	Relevant to claim No.		
Υ	WO 94/19017 (A1 PROGENICS PI 01 September 1994 (01.09.94		1-55		
Y	US 5,359,046 A (CAPON et al.) 25 October 1994, see entire document.				
Y SHIN. Chimeric Antibody: Potential Applications for Drug Delivery and Immmunotherapy. Biotherapy, 1991, Vol. 3, pages 43-53, see entire document.			1-55		
Y	SHIN et al. Functional Propertie Growth Factor Fusion Proteins. Chemistry. 18 February 1994, Vol 4985, see entire document.	The Journal of Biological	1-55		
X Furth	X Further documents are listed in the continuation of Box C. See patent family annex.				
Special categories of cited documents:  "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention					
to	to be of particular relevance				
"L" do	considered novel or cannot be considered to involve an inventive step				
	cited to establish the publication date of another citation or other special reason (as specified)  "Y"  document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is				
	cument published prior to the international filing date but later than priority date claimed	*&* document member of the same patent	family		
Date of the	actual completion of the international search	Date of mailing of the international sea	arch report		
07 APRIL	. 1997	2 7 MAY 1997			
	nailing address of the ISA/US ner of Patents and Trademarks	Authorized officer IW For	•		
Washington	n, D.C. 20231	EVELYN M. RABIN			
Facsimile N	o. (703) 305-3230	Telephone No. (703)-308-0196			

### INTERNATIONAL SEARCH REPORT

International application No. PCT/US96/20577

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.					
Y	BEI et al. Baculovirus Expression of a Functional Single-chain Immunoglobulin and Its IL-2 Fusion Protein. Journal of Immunological Methods. 26 October 1995, Vol. 186, pages 245-255, see entire document.	1-55					
Y	CHEON et al. High-affinity Binding Sites for Related Fibroblast Growth Factor Ligands Reside Within Different Receptor Immunoglobulin-like Domains. Proc. Natl. Acad. Sci. USA. February 1994, Vol. 91, pages 989-993, see entire document.	1-55					
Y	BACKSTROM et al. Characterization of an Internal Permissive Site in the Cholera Toxin B-subunit and Insertion of Epitopes from Human Immunodeficiency Virus-1, Hepatitis B Virus and Enterotoxigenic Escherichia coli. Gene. Vol. 165, pages 163-171, see entire document.	1-55					
Y	DE LORIMIER et al. NMR-Derived Solution Conformations of a Hybrid Synthetic Peptide Containing Multiple Epitopes of Envelope Protein gp120 from the RF Strain of Human Immunodeficiency Virus. Biochemistry. March 1994, Vol. 33, pages 2055-2062, see entire document.	1-55					
Y	DUARTE et al. Multiepitope Polypeptide of the HIV-1 Envelope Induces Neutralizing Monoclonal Antibodies against V3 Loop. AIDS Research and Human Retroviruses, 1994, Vol. 10, No. 3, pages 235-243, see entire document.	1-55					
Y	HEARST et al. GRAFTER: a Computational Aid for the Design of Novel Proteins. Protein Engineering, 1994, Vol. 7, No. 12, pages 1411-1421, see entire document.	1-55					

### INTERNATIONAL SEARCH REPORT

International application No. PCT/US96/20577

CO7K 1/00, 14/00, 16/00, 17/00; C12P 21/02, 21/04, 21/08; A61K 39/395, 39/40, 39/42, 38/00; G01N 33/53  A. CLASSIFICATION OF SUBJECT MATTER: US CL:  530/350, 387.3, 388.25, 388.7; 424/133.1, 145.1, 152.1, 159.1; 514/12; 435/7.1, 69.5, 69.7
US CL: 530/350, 387.3, 388.25, 388.7; 424/133.1, 145.1, 152.1, 159.1; 514/12; 435/7.1, 69.5, 69.7

Form PCT/ISA/210 (extra sheet)(July 1992)★

US 0909157817P1 ·



Creation date: 01-05-2004

Indexing Officer: KNANCE - KERMIT NANCE

Team: OIPEBackFileIndexing

Dossier: 09091578

Legal Date: 08-03-1998

No.	Doccode	Number of pages
1	M905	1

Total number of pages: 1

Remarks:

Order of re-scan issued on .....